LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the “Company”)(OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that the Company completed production of a sufficient amount of CytoFeline™, a monoclonal antibody developed by the Company for the treatment of Feline Immunodeficiency Virus (“FIV”), to allow the Company, through its wholly owned subsidiary, CytoDyn Veterinary Medicine LLC (“CVM”), to move forward with the next stage of the antibody’s development. When purification of the antibody is completed, CVM will conduct in vivo efficacy tests in cats to determine the practicality of anti-LFA1 antibodies to lower viral loads in FIV-infected cats.
